Latest Research Evaluating VASCEPA/VAZKEPA And Subgroups From The REDUCE-IT Landmark Outcomes Trial To Be Presented At The American Heart Association Scientific Sessions 2023
Portfolio Pulse from Benzinga Newsdesk
Amarin Corporation (NASDAQ:AMRN) announced that new research from the REDUCE-IT cardiovascular outcomes trial on the effects of VASCEPA/VAZKEPA in specific patient subgroups has been accepted for presentation at the American Heart Association (AHA) Scientific Sessions 2023. The research includes a presentation on the reduction in first and total CV events following treatment with VASCEPA/VAZKEPA in a high-risk patient subgroup with a history of Metabolic Syndrome but without diabetes.
October 26, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The acceptance of Amarin's new research for presentation at a prestigious event like the AHA Scientific Sessions could potentially boost the company's reputation and increase investor confidence.
The acceptance of Amarin's research for presentation at a prestigious event like the AHA Scientific Sessions indicates the significance of the research and the potential impact of VASCEPA/VAZKEPA on specific patient subgroups. This could potentially boost the company's reputation in the medical and scientific community, and increase investor confidence in the company's products and research capabilities.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100